-transparent.png){kind=logo}
The presence of motility inhibitors in seminal plasma and within spermatozoa from control and infertile men with poor sperm motility was investigated using demembranated reactivated human spermatozoa. No difference was found in the inhibitory capacities in seminal plasma of patients with poor sperm motility (less than 50%) when compared with that of fertile controls with motility above 50%. No correlation was observed between inhibitory capacity and sperm motility. However, when extracts of spermatozoa from these patients were tested for the presence of inhibitor, it was observed that three of nine patients had an inhibitor in their sperm extract. By contrast, all sperm extracts from fertile control subjects were devoid of inhibitor. It was concluded that the presence of a motility inhibitor in seminal plasma does not explain the poor sperm motility observed in patients. The presence of a motility inhibitor within spermatozoa, however, may represent an important factor in the etiology of the poor sperm motility observed in some patients.
E de Lamirande, and
R J Sherins, and
C Gagnon
July 1987,
Fertility and sterility,
E de Lamirande, and
R J Sherins, and
C Gagnon
March 2003,
Fertility and sterility,
E de Lamirande, and
R J Sherins, and
C Gagnon
November 2001,
The New England journal of medicine,
E de Lamirande, and
R J Sherins, and
C Gagnon
January 1990,
Andrologia,
E de Lamirande, and
R J Sherins, and
C Gagnon
January 2013,
Journal of human reproductive sciences,
E de Lamirande, and
R J Sherins, and
C Gagnon
December 2014,
Urology,
E de Lamirande, and
R J Sherins, and
C Gagnon
March 2022,
Andrologia,
E de Lamirande, and
R J Sherins, and
C Gagnon
February 2019,
Human reproduction (Oxford, England),
E de Lamirande, and
R J Sherins, and
C Gagnon
January 1989,
Andrologia,
E de Lamirande, and
R J Sherins, and
C Gagnon
October 1987,
Lancet (London, England),
